Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.

Leading provider of Drug Discovery Ontologies BioWisdom Ltd has announced that Oliver Bayliss has been appointed as Director of Sales and Business Development.

Bayliss will spearhead the expansion of BioWisdom’s worldwide direct sales operation using experience gained in his positions at Viaken Systems, Accelrys, GCG, Oxford Molecular and DNAStar. He will also develop and manage BioWisdom’s channel strategies, working with a variety of scientific application and content providers to deliver BioWisdom’s ontologies through a range of third party tools.

“BioWisdom is providing its customers with very high quality, expertly annotated ontologies focussed on drug discovery. These ontologies underpin a number of critical R&D functions, including effective searching, integration and navigation through the complex research information pool. These tools empower both expert informaticians and end-users alike,” said Bayliss. “I am very excited about joining the BioWisdom senior executive team and look forward to helping the company continue the strong growth of new pharmaceutical and biotech customers.”

“This is a very timely appointment in BioWisdom’s development. Our Discovery Ontologies are being deployed more widely in both Europe and the US. Oliver has over ten years international experience in sales and business development for life science informatics companies,” said Dr Gordon Smith Baxter, CEO of BioWisdom. “He has a breadth of commercial skills, having successfully built sales teams and developed new markets for a number of discovery solution providers.”

About BioWisdom

BioWisdom Ltd., headquartered in Cambridge UK, established in September 2000, is a biomedical informatics company developing systems which help R&D professionals to access critical information and to assist them in the discovery and development of novel drug therapies. BioWisdom produces powerful life science ontologies, which describe important discovery concepts such as targets (e.g. genes and proteins) tissues and disease and the inter-relationships between them. BioWisdom’s Discovery Ontologies deliver improved searching, integration and navigation through complex research information.

-ENDS-





For further information, please contact:

Gordon Smith Baxter, CEO
BioWisdom Ltd
Tel: +44 (0)1223 492100
email: gordon.baxter@biowisdom.com
http://www.biowisdom.com

This press release was distributed by ResponseSource Press Release Wire on behalf of BioWisdom Ltd in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.